Arcturus Therapeutics

Arcturus Therapeutics News & Events

Ultragenyx Pharmaceutical and Arcturus Therapeutics Announce a Research Collaboration and License Agreement to Develop RNA Therapeutics for Rare Diseases

October 29, 2015

NOVATO, CA – October 29, 2015 – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Arcturus Therapeutics, Inc., a leading RNA medicines company, today announced that they have entered into a research collaboration and license agreement to discover and develop messenger RNA […]

Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications

June 11, 2015

San Diego, Calif., June 11, 2015 – Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the agreement, facilitated by J&J Innovation, the parties will work together to develop and commercialize RNA-based drug products for the […]

Precision NanoSystems and Arcturus Therapeutics Announce a Partnership for the Manufacture of RNA Medicines

January 9, 2015

Vancouver, Canada, Jan 9, 2015 – Precision NanoSystems, a leader in the development and application of microfluidics for the manufacture of nanomedicines; and, Arcturus Therapeutics, a leading small interfering RNA (siRNA) and messenger RNA (mRNA) drug discovery and development company, today announced a partnership for the manufacture of RNA medicines. Under the terms of the […]

Arcturus Therapeutics to Present Messenger RNA Pipeline at the 33rd Annual J.P. Morgan Healthcare Conference and the 7th Annual Biotech Showcase

January 7, 2015

Announces new messenger RNA therapeutics pipeline using LUNAR™ delivery technology and UNA-messenger RNA (UmRNA) Messenger RNA pipeline programs include thrombopoietin (LUNAR-TPO) for the management of thrombocytopenia, ornithine transcarbamylase (LUNAR-OTC) for the treatment of ornithine transcarbamylase deficiency, hepcidin (LUNAR-HPN) for the treatment of iron disorders, and cystic fibrosis transmembrane conductance regulator (LUNAR-CF) for the treatment of […]